RITA Medical Systems Announces Relocation of Corporate Headquarters; Company Moves from Mountain View, Calif. to New Offices in Fremont, Calif.
| RITA Medical Systems Announces Relocation of Corporate Headquarters; Company Moves from Mountain View, Calif. to New Offices in Fremont, Calif. |
 |
FREMONT, Calif.--(BUSINESS WIRE)--May 2, 2005--RITA Medical Systems, Inc. (Nasdaq:RITA), a leader in medical oncology devices, today announced that the Company's headquarters were relocated to Fremont, California effective Monday, May 2, 2005. The company has leased the new 14,400 sq. ft. office for a term of five years. The new address is 46421 Landing Parkway, Fremont, California, 94538, and the telephone number is (510) 771-0400. About RITA Medical Systems, Inc. RITA Medical Systems develops manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex® technology; tunneled central venous catheters; safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA Company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone. The statements in this news release related to medical oncology devices are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks is included in the Company's filings with the Securities and Exchange Commission.
|